Excess fatality from desipramine and dosage recommendations

Therapeutic Drug Monitoring

Volumn 26, Issue 5, 2004, Pages 468-473

  Amitai, Yona ^a   Frischer, Henri ^b  

^a MINISTRY OF HEALTH   (Israel)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Desipramine; Dose; Mortality; Plasma level

Indexed keywords

AMITRIPTYLINE; DESIPRAMINE; IMIPRAMINE; NORTRIPTYLINE;

ARTICLE; DATA BASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG OVERDOSE; DRUG SCREENING; ERYTHROCYTE; HUMAN; MORTALITY; POISON CENTER; PRIORITY JOURNAL; UNITED KINGDOM; UNITED STATES;

AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DATABASES, FACTUAL; DESIPRAMINE; GREAT BRITAIN; HUMANS; IMIPRAMINE; NORTRIPTYLINE; OVERDOSE; UNITED STATES;

EID: 4744356103     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200410000-00002     Document Type: Article

References (59)

1. Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. BMJ. 1987;295:1021-1024.
2. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ. 1995;310:221-224.
3. Buckley NA, McManus PR. Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998;18:369-381.
4. Kapur S, Mieczkowski T, Mann J. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA. 1992;268:3441-3445.
5. Amitai Y, Frischer H. The toxicity and dose of desipramine hydrochloride. JAMA. 1994;272:1719-1720.
6. Rose JC, Unis AS. A mortality index for post marketing surveillance of new medications. Am J Emerg Med. 2000;18:176-179.
7. Amitai Y, Frischer H. Excess fatality from desipramine and dosage recommendations. J Toxicol Clin Toxicol. 2003;5:714. Abstract 176.
8. Riddle MA, Nelson C, Kleinman CS, et al. Sudden death in children receiving Norpramin: A review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry. 1991;30:104-108.
9. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry. 1993;32:792-797.
10. Werry HS, Biederman J, Thisted R, et al. Debate Forum. Resolved: Cardiac arrhythmias make desipramine an unacceptable choice in children. J Am Acad Child Adolesc Psychiatry. 1995;34:1239-1245; discussion 1245-1248.
11. Varley CK. Sudden deaths related to selected tricyclic antidepressants in children. Paediatr Drugs. 2001;3:613-627.
12. The PedTox Registry of the National Association of Medical Examiners (NAME) has reviewed 15 cases of death associated with desipramine in children; 10 deaths were attributed to the drug (www.thename. org/pedtox_index.htm).
13. Veltry JC, Litovitz TL. 1983 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. 1984;2:420-443.
14. Litovitz T, Veltri JC. 1984 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. 1985;3:423-450.
15. Litovitz TL. Normann SA, Veltri JC. 1985 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. 1986;4:427-458.
16. Litovitz TL, Martin TG, Schmitz B. 1986 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. 1987;5:405-445.
17. Litovitz TL, Schmitz B, Matyunas N, et al. 1987 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. 1988;6:479-515.
18. Litovitz TL, Schmitz B, Holm KC. 1988 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. 1989;7:495-545.
19. Litovitz TI, Schmitz B, Bailey KM. 1989 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. 1990;8:394-442.
20. Litovitz TL, Bailey KM, Schmitz B, et al. 1990 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. 1991;9:461-509.
21. Litovitz TL, Holm KC, Bailey KM, et al. 1991 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. 1992;10:452-505.
22. Litovitz TL, Holm KC, Clancy C, et al. 1992 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1993;11:494-555.
23. Litovitz TL, Clark LR, Soloway RA. 1993 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1994;12:546-584.
24. Litovitz TL, Felberg L, Soloway RA, et al. 1994 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1995;13:551-597.
25. Litovitz TL, Felberg L, White S, et al. 1995 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1996;14:487-537.
26. Litovitz TL, Smilkstein M, Felberg L, et al. 1996 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1997;15:447-500.
27. Litovitz TL, Dyer KS, Shannon M, et al. 1997 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1998;16:443-497.
28. Litovitz TL, Klein-Schwartz W, Caravati EM, et al. 1998 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1999;17:435-487.
29. Litovitz TL, Klein-Schwartz W, White S, et al. 1999 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2000;18:517-574.
30. Litovitz TL, Klein-Schwartz W, White S, et al. 2000 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2001;19:337-395.
31. Litovitz TL, Klein-Schwartz W, Cobaugh DJ, et al. 2001 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2002;20:391-452.
32. Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2003;21:353-421.
33. Dahl ML, Iselius L, Aim C, et al. Polymorphic 2-hydroxylation of desipramine. A population study. Eur J Clin Pharmacol. 1993;44:445-450.
34. Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isoenzymes. Drug Metab Dispos. 1997;25:740-744.
35. Kvist EE, Al-Shurbaji A, Dahl ML, et al. Quantitative pharmacogenetics of nortriptyline: a novel approach. Clin Pharmacokinet. 2001;40:869-877.
36. Breyer-Pfaff U, Pfandl B, Nill K, et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isoenzymes. Clin Pharmacol Ther. 1992;52:350-358.
37. Venkatakrishnan K, Schmider J, Harmatz JS, et al. Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. Clin Pharmacol. 2001;41:1043-1054.
38. Koyama E, hiba K, Tani M, Ishizaki T. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997;281:1199-1210.
39. Coutts RT, Bach MV, Baker GB. Metabolism of amitriptyline with CYP2D6 expressed in a human cell line. Xenobiotica. 1997;27:33-47.
40. Deleted in proof.
41. Deleted in proof.
42. Deleted in proof.
43. Bertilsson L, Dahl ML, Dalen P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53:111-122.
44. Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descendent throughout the world. Pharmacogenetics. 1999;9:539-549.
45. Biederman J, Goldblatt A. A double-blind placebo controlled study of desipramine in the treatment of attention deficit disorder II: serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry. 1989;28:903-911.
46. Wilens TE, Biederman J, Baldessarini RJ, et al. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents and adults treated with desipramine. J Am Acad Child Adolesc Psychiatry. 1993;32:798-804.
47. Amsterdam JD, Brunswick DJ, Potter L, et al. Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients. Lack of correlation with therapeutic response. Arch Gen Psychiatry. 1985;42: 361-364.
48. Coppen H, Montgomery S, Ghose K, et al. Amitriptyline plasma concentrations and clinical effects. A World Health Collaborative Study. Lancet. 1978;1:63-68.
49. Bailey DN, VanDyke C, Langou RA, et al. Tricyclic antidepressants. Plasma levels and clinical findings in overdose. Am J Psychiatry. 1978; 135:1325-1328.
50. Boehnert MT, Lovejoy FH. Value of QRS duration versus serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose in tricyclic antidepressants. N Engl J Med. 1985;313:474-479.
51. Lavoie FW, Gansert GG, Weiss RE. Value of initial ECG findings and plasma drug level in cyclic antidepressant overdose. Ann Emerg Med. 1990;19:696-700.
52. Matuzas W, Javaid JI, Uhlenhuth EH, et al. Plasma and red blood cell imipramine levels and clinical response among depressed patients. Psychopharmacol Bull. 1983;19:652-655.
53. Amitai Y, Frischer H, Kennedy EJ, et al. Tricyclic antidepressants in red cells and plasma: Correlation with impaired intraventricular conduction in acute overdose. Clin Pharmacol Ther. 1993;54:219-227.
54. Nelson JC, Jatlow PI. Nonlinear desipramine kinetics; prevalence and importance. Clin Pharmacol Ther. 1987;41:666-670.
55. Sindrup SH, Brosen K, Gram LF. Nonlinear kinetics of imipramine in low and medium plasma level range. Ther Drug Monit. 1990;12:445-449.
56. Jerling M, Avlan G. Nonlinear kinetics of nortriptyline in relation to nortriptyline clearance as observed during therapeutic drug monitoring. Eur J Clin Pharmacol. 1994;46:67-70.
57. Benet LZ, Williams ARL. Design and optimization of dosage regimens: pharmacokinetic data. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 8th ed. New York: Pergamon Press; 1990:1673.
58. Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill; 1996: 1733.
59. Hoppe-Roberts JM, Lloyd LM, Chyka PA. Poisoning mortality in the United States: Comparison of national mortality statistics and poison control center reports. Ann Emerg Med. 2000;35:440-448.